Cetuximab enhances response in KRAS (KRAS proto-oncogene) wild type metastatic colorectal cancer. This trial selected patients with KRAS wild type rectal cancer to assess added benefit from cetuximab in the neoadjuvant setting. Pathologic complete response (pCR) was the surrogate for benefit. Eighty patients were enrolled targeting a pCR rate of 35%, an outcome that was not achieved. This regimen cannot be recommended for general use. Background: Neoadjuvant chemoradiation (NCRT) is standard treatment for locally advanced rectal cancer. Pathologic complete response (pCR) has associated with improved survival. In modern phase III trials of NCRT, pCR ranges from 10% to 20%. Cetuximab improves response in KRAS (KRAS proto-oncogene) wild type (wt) metastatic colorectal cancer. S0713 was designed to assess improvement in pCR with additional use of cetuximab with induction chemotherapy and NCRT for locally advanced, KRAS-wt rectal cancer. Patients and Methods: Patient eligibility: stage II to III biopsy-proven, KRAS-wt rectal adenocarcinoma; no bowel obstruction; adequate hematologic, hepatic and renal function; performance status of 0 to 2. Target enrollment: 80 patients. Treatment: induction chemotherapy with wCAPOX (weekly capecitabine and oxaliplatin) and cetuximab followed by the same regimen concurrent with radiation (omitting day 15 oxaliplatin). If fewer than 7 pCRs were observed at planned interim analysis after 40 patients received all therapy, the study would close. Eighty eligible patients would provide 90% power given a true pCR rate > 35% at a significance of 0.04. The regimen would lack future interest if pCR probability was 20%. Results: Between February 2009 and April 2013, 83 patients registered. Four were ineligible and 4 not treated, leaving 75 evaluable for clinical outcomes and toxicity, of whom 65 had surgery. Of 75 patients, 20 had pCR (27%; 95% confidence interval [CI], 17%-38%); 19 (25%) had microscopic cancer; 36 (48%) had minor/no response (including 10 without surgery). Three-year disease-free survival was 73% (95% CI, 63%-83%). Conclusion: Our trial did not meet the pCR target of 35%. Toxicity was generally acceptable. This regimen cannot be recommended outside the clinical trial setting.
Introduction
With total mesorectal excision (TME) and neoadjuvant chemoradiation as standard therapy, local control for rectal adenocarcinoma has greatly improved compared with historical postoperative chemotherapy and radiation. 1 Unfortunately, distant recurrence rates remain stable in the 25% to 35% range. 2 Adjuvant trial design for rectal cancer derives from colon cancer trials, in which additional use of oxaliplatin with fluoropyrimidine therapy has provided survival benefit. 3, 4 However, for rectal cancer, oxaliplatin has failed to improve outcomes in most randomized trials. [5] [6] [7] [8] [9] Many patients with residual cancer after neoadjuvant chemoradiation do not receive adjuvant treatment because of prolonged surgical recovery. 10, 11 Administering planned adjuvant chemotherapy in the preoperative setting might address this. 12, 13 The neoadjuvant approach allows efficacy evaluation via pathologic response assessment. In many cancers, pathologic complete response (pCR) correlates with improved outcome and is considered a surrogate of therapeutic benefit in signal-seeking phase II trials. 14, 15 Thus, scheduling chemotherapy before chemoradiation to increase pCR is reasonable. 16 We designed a trial for locally advanced KRAS wild type (wt) adenocarcinoma of the rectum. Cetuximab was investigated on the basis of demonstrated benefit in KRAS-wt metastatic colon cancer. 17, 18 At this trial's inception, oxaliplatin was being investigated in neoadjuvant chemoradiation trials for rectal cancer. 19 Additionally, we planned a course of induction chemotherapy before chemoradiation to determine if increased chemotherapy exposure could enhance pCR rate.
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Patients and Methods
The primary objective of this trial was to assess pCR in patients with stage II to III KRAS-wt adenocarcinoma of the rectum treated with wCAPOX (weekly capecitabine and oxaliplatin) and cetuximab given as induction therapy followed by the same regimen concurrent with external beam radiotherapy to the pelvis. Secondary objectives included estimation of 3-year disease-free survival (DFS) and the frequency and severity of toxicities. Cetuximab Combined With Induction CAPOX, Followed by NCRT Primary eligibility criteria were biopsy proven, untreated KRASwt stage II to III rectal cancer with adequate performance status and organ function. Other inclusion and exclusion criteria are listed in the study protocol. Before registration, tumor tissue was submitted to a Clinical Laboratory Improvement Amendments-certified laboratory to confirm KRAS-wt status. All patients were evaluated by the medical, surgical, and radiation oncologists providing treatment before the initiation of therapy. Site institutional review board approval and patient written informed consent was obtained before trial enrollment.
The protocol consisted of: cycle 1 induction chemotherapy (days 1-35) followed by a 14-day rest period; cycle 2 chemoradiation (days 50-84); and surgery ( Figure 1 Monday through Friday of all chemotherapy cycles. External beam radiotherapy 180 centigray (cGy) daily, Monday through Friday for 25 fractions, began concurrently with the second chemotherapy cycle. A 540-cGy boost was delivered in three 180-cGy fractions for patients with clinical T3 cancers (total dose 5040 cGy), and 900 cGy in five 180-cGy fractions for patients with clinical T4 cancers (total dose, 5400 cGy). Central review of the radiation treatment plan was required before initiation of therapy, with a final review occurring after protocol completion.
Surgery was to occur between 3 and 8 weeks of chemoradiation completion. TME principles were applied with sphincter preservation as a goal.
The primary statistical end point was pCR. The regimen would be considered of further interest if the pCR rate was 35%, and of no further interest if 20%. Eighty eligible patients were needed to provide 90% power with a true pCR rate > 35% at a significance of 0.04 on the basis of the Southwestern Oncology Group 2-stage design. 20 Those without surgery were assumed not to have achieved pCR. An interim analysis was planned after response data for the first 40 patients treated became available: 7 pCRs or failure of 25% of this cohort to complete protocol therapy would result in study closure. DFS was estimated using the method of Kaplan and Meier. DFS, defined as freedom from death, local, and/or distant disease recurrence, was measured from the time of registration and censored at the date of last contact. For toxicity/safety analysis, 80 patients were adequate to estimate that any toxicity with a 5% occurrence rate was likely (98%) to be seen at least once.
Results
Between February 2009 and April 2013, 83 patients from 20 institutions were registered in this trial. Reasons for ineligibility included: inadequate baseline disease assessment (n ¼ 2), location of disease (n ¼ 1), and distant metastases (n ¼ 1). Four patients who received no protocol therapy were not included in any study analyses.
Seventy-five patients are included in the final analysis, including 2 patients without documentation of KRAS-wt status and 1 without a baseline radiology report. Eleven patients were removed from protocol therapy before completion of all protocol treatment due to toxicity-primarily gastrointestinal (7 patients), refusal to undergo chemoradiation, noncompliance, progression, and death (1 patient each).
Demographic characteristics for the 75 eligible patients who received therapy are summarized in Table 1 .
Sixty-five patients (87%) underwent surgery. Of those who did not undergo surgery, subsequent review showed 3 of these who died due to disease progression, 2 to have died from other causes, and 5 to be without evidence of disease at last follow-up submission, 2 of whom had nonprotocol surgery.
Twenty patients (27% [95% confidence interval {CI}, 17%-38%]) achieved a pCR at surgery. The protocol-specified historical rate of pCR was 20%; a 1-sided exact binomial test of the observed pCR rate compared with the historical rate gave P ¼ .10. Nineteen additional patients (25%) had microscopic cancer, and 36 patients (48%) were coded non-responders (including minimal or partial responses according to trial design). The 3-year DFS was 73% (95% CI, 63%-83%; Figure 2 ).
Toxicity
Seventy-five patients were included in the adverse event analysis. Dominant side effects were gastrointestinal, integumentary, and neurologic. Hematologic toxicity was rare. Grade 3 events occurring in at least 10% of patients were diarrhea, nausea/vomiting, rash, hypokalemia, and lymphopenia. Two patients experienced Grade 4 events: dehydration, and colitis with hyponatremia. One death from multiorgan failure with associated Grade 4 acidosis, dehydration, and diarrhea was considered possibly related to study treatment. Adverse events are listed in Table 2 .
Discussion
This single-arm phase II trial to assess the additional use of cetuximab with wCAPOX and radiation in a selected KRAS-wt rectal cancer population failed to meet the primary end point of a 35% pCR rate. Patient ineligibility and dropout were higher than anticipated in our trial resulting in a smaller than anticipated evaluable cohort. The effect of nonsurgical cases (n ¼ 10 of the 75 eligible) on pCR cannot be known, although at the time of publication some of these patients remain alive without evidence of disease.
In results published since our trial began, the additional use of oxaliplatin with neoadjuvant 5efluorouracil-based chemoradiation for locally advanced rectal cancer failed to show added benefit, assessed according to pCR rate, in all but 1 large randomized trial (CAO/ARO/AIO-04). [5] [6] [7] [8] [9] In these trials, patients who received oxaliplatin experienced more frequent and higher-Grade toxicities. Although oxaliplatin toxicity could potentially have negated cetuximab benefit, several small previously reported phase II trials that integrated cetuximab with neoadjuvant capecitabine and radiation reported pCR rates not significantly increased over historical rates with chemoradiation alone. [21] [22] [23] Additionally, a pooled analysis of 3 preoperative phase I/II trials of radiation and CAPOX (capecitabine and oxaliplatin), with or without cetuximab, suggested a possible negative interaction from cetuximab. 24 Previously reported rectal cancer trials have assessed the effect of additional use of cetuximab with neoadjuvant fluoropyrimidine, oxaliplatin, and radiation in an effort to enhance pCR rate. In one such phase I/II trial that did not report an increased pCR signal, the authors suggested the order of treatment administration might affect efficacy. 25 Recent investigation has shown that radiation can increase the release of tumor antigens allowing an immune response to occur. 26 Possibly, chemoradiation would be more effective if administered first. Radiosensitization was another rationale for investigating cetuximab. 27 Nonetheless, chemoradiation with cetuximab failed to eradicate cancer in 73 of the patients in this trial. Results from this and similar trials that used cetuximab in addition to preoperative rectal cancer therapy are similar to results with chemoradiation alone, implying little sensitization benefit. Although pCR has been associated with improved survival, its surrogacy has recently been called into question. 28, 29 pCR does not capture microscopic-only disease, which, in an analysis of tumor regression grading systems, has a positive effect on outcome.
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The EXPERT-C trial included 160 patients randomized to CAPOX or CAPOX with cetuximab, with pCR as the primary end point. Although the additional use of cetuximab with neoadjuvant CAPOX improved overall response rate (71% vs. 51% after chemotherapy, P ¼ .038; and 93% vs. 75% after chemoradiation, P ¼ .028) and overall survival (hazard ratio, 0.27; P ¼ .034), no effect on pCR was observed (11% vs. 9%; P ¼ .99). 31 The authors concluded that although their results were promising, they could not recommend this regimen for standard use.
Conclusion
Although the pCR result in our trial compared favorably with recent historical data, it neither met its prespecified end point, nor produced results clinically meaningful enough to recommend the additional use of cetuximab with current standard neoadjuvant chemoradiation in a KRAS-wt, stage II to III rectal cancer population. Further genomic, proteomic, and epigenetic analyses from ongoing investigations will be necessary to overcome the current lack of progress in the treatment of curable rectal cancer. 
